Overview

Prevention of Oral Mucositis (SPOM)

Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
1. Study Design - Prospective, Randomized, Questionnaire-Based Study - Study Type: Interventional Clinical Trial - Intervention Model: Parallel Assignment - Masking: None (Open label) - Actual Enrollment: 88 participants - Allocation: Randomized - Primary Purpose: Supportive Care/Treatment Study groups Group 1-Standard oral care +/- Bocaliner Group 2 Benzydamine mouthwash +/- Bocaliner 2. Settings - Single center (a specialized hematology center) - Location: Yeolyan Hematology Center, 7 Nersisyan St, Yerevan 0014, Armenia - Subjects will initially be enrolled, consented, examined and complete initial questionnaires in the healthcare provider's office Subjects will undergo initial evaluation and follow up examinations to determine WHO Oral Mucositis Scores - Subjects will complete questionnaires at the medical center with the Research Coordinator 7, 14, and 21 days after study enrollment. Subjects using Bocalinerâ„¢ will additionally complete a follow-up questionnaire. - Application of Bocalinerâ„¢ will be carried out first at the hospital followed by self-administration at home.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
E2Bio Life Sciences, LLC
Collaborator:
Hematology Center after Prof. R. Yeolyan
Treatments:
Anti-Bacterial Agents
Anti-Inflammatory Agents
Benzydamine